1
|
Zhou K, Gu X, Tan H, Yu T, Liu C, Ding Z, Liu J, Shi H. Identification pyroptosis-related gene signature to predict prognosis and associated regulation axis in colon cancer. Front Pharmacol 2022; 13:1004425. [PMID: 36249755 PMCID: PMC9559861 DOI: 10.3389/fphar.2022.1004425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2022] [Accepted: 09/07/2022] [Indexed: 12/01/2022] Open
Abstract
Background: Pyroptosis is an important component of the tumor microenvironment and associated with the occurrence and progression of cancer. As the expression of pyroptosis-related genes and its impact on the prognosis of colon cancer (CC) remains unclear, we constructed and validated a pyroptosis-related genes signature to predict the prognosis of patients with CC. Methods: Microarray datasets and the follow-up clinical information of CC patients were obtained from the Gene Expression Omnibus (GEO) and the Cancer Genome Atlas (TCGA) databases. Candidate genes were screened out for further analysis. Various methods were combined to construct a robust pyroptosis-related genes signature for predicting the prognosis of patients with CC. Based on the gene signature and clinical features, a decision tree and nomogram were developed to improve risk stratification and quantify risk assessment for individual patients. Results: The pyroptosis-related genes signature successfully discriminated CC patients with high-risk in the training cohorts. The prognostic value of this signature was further confirmed in independent validation cohort. Multivariable Cox regression and stratified survival analysis revealed this signature was an independent prognostic factor for CC patients. The decision tree identified risk subgroups powerfully, and the nomogram incorporating the gene signature and clinical risk factors performed well in the calibration plots. Conclusion: Pyroptosis-related genes signature was an independent prognostic factor, and can be used to predict the prognosis of patients with CC.
Collapse
Affiliation(s)
- Kexun Zhou
- Department of Radiotherapy, Cancer Center, West China Hospital, Sichuan University, China
| | - Xuyu Gu
- School of Medicine, Southeast University, Nanjing, China
| | - Huaicheng Tan
- Department of Radiotherapy, Cancer Center, West China Hospital, Sichuan University, China
| | - Ting Yu
- Department of Pathology and Laboratory of Pathology, State Key Laboratory of Biotherapy, West China Hospital, West China School of Medicine, Sichuan University, China
| | - Chunhua Liu
- Department of Radiotherapy, Cancer Center, West China Hospital, Sichuan University, China
| | - Zhenyu Ding
- Department of Radiotherapy, Cancer Center, West China Hospital, Sichuan University, China
| | - Jiyan Liu
- Department of Radiotherapy, Cancer Center, West China Hospital, Sichuan University, China
| | - Huashan Shi
- Department of Radiotherapy, Cancer Center, West China Hospital, Sichuan University, China
- Department of Radiotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, China
- *Correspondence: Huashan Shi,
| |
Collapse
|
2
|
Myers RE, Wolf T, Shwae P, Hegarty S, Peiper SC, Waldman SA. A survey of physician receptivity to molecular diagnostic testing and readiness to act on results for early-stage colon cancer patients. BMC Cancer 2016; 16:766. [PMID: 27716119 PMCID: PMC5048478 DOI: 10.1186/s12885-016-2812-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2015] [Accepted: 09/23/2016] [Indexed: 12/20/2022] Open
Abstract
Background We sought to assess physician interest in molecular prognosic testing for patients with early stage colon cancer, and identify factors associated with the likelihood of test adoption. Methods We identified physicians who care for patients with early-stage (pN0) colon cancer patients, mailed them a survey, and analyzed survey responses to assess clinician receptivity to the use of a new molecular test (GUCY2C) that identifies patients at risk for recurrence, and clinician readiness to act on abnormal test results. Results Of 104 eligible potential respondents, 41 completed and returned the survey. Among responding physicians, 56 % were receptive to using the new prognostic test. Multivariable analyses showed that physicians in academic medical centers were significantly more receptive to molecular test use than those in non-academic settings. Forty-one percent of respondents were ready to act on abnormal molecular test results. Physicians who viewed current staging methods as inaccurate and were confident in their capacity to incorporate molecular testing in practice were more likely to say they would act on abnormal test results. Conclusions Physician receptivity to molecular diagnostic testing for early-stage colon cancer patients is likely to be influenced by practice setting and perceptions related to delivering quality care to patients. Trial registration ClinicalTrials.gov Identifier: NCT01972737
Collapse
Affiliation(s)
- Ronald E Myers
- Department of Medical Oncology, Thomas Jefferson University, Benjamin Franklin House, Suite 314, 834 Chestnut St, Philadelphia, PA, 19107, USA.
| | - Thomas Wolf
- Department of Medical Oncology, Thomas Jefferson University, Benjamin Franklin House, Suite 314, 834 Chestnut St, Philadelphia, PA, 19107, USA
| | - Phillip Shwae
- Thomas Jefferson University, 305 South 11th Street, Apt. 4F, Philadelphia, PA, 19107, USA
| | - Sarah Hegarty
- Department of Pharmacology & Experimental Therapeutics, Thomas Jefferson University, 1015 Chestnut Street Building, Suite M-100 Mezzanine, 1015 Chestnut Street, Philadelphia, PA, 19107, USA
| | - Stephen C Peiper
- Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Jeff Hall, Room 279, 1020 Locust St, Philadelphia, PA, 19107, USA
| | - Scott A Waldman
- Department of Pharmacology & Experimental Therapeutics, Thomas Jefferson University, 1015 Chestnut Street Building, Suite M-100 Mezzanine, 1015 Chestnut Street, Philadelphia, PA, 19107, USA
| |
Collapse
|
3
|
Wang HX, Tao LY, Qi KE, Zhang HY, Feng D, Wei WJ, Kong H, Chen TW, Lin QS, Chen DJ. Role of CXC chemokine receptor type 7 in carcinogenesis and lymph node metastasis of colon cancer. Mol Clin Oncol 2015; 3:1229-1232. [PMID: 26807225 DOI: 10.3892/mco.2015.643] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2015] [Accepted: 05/29/2015] [Indexed: 12/11/2022] Open
Abstract
Upregulated expression of the CXC chemokine receptor type 7 (CXCR7) promotes breast, lung and prostate cancer progression and metastasis. However, the role of CXCR7 in colon cancer has not been determined. We hypothesized that increased CXCR7 expression may contribute to human colon cancer occurrence and progression. Reverse transcription quantitative polymerase chain reaction and western blot analysis were performed on 34 malignant and 18 normal colon tissue specimens. The specimens were obtained from 19 male and 15 female patients, with a mean age of 52 years (range, 34-79 years). Of the 34 patients, 20 had lymph node metastases. None of the patients had received adjuvant radiotherapy or chemotherapy prior to surgery. This study demonstrated that CXCR7 levels were significantly higher in colon tumors compared with those in normal colon tissue (P﹤0.01). In addition, lymph node metastatic colon tumors exhibited significantly higher CXCR7 expression compared with non-metastatic tumors (P﹤0.01); however, there were no differences in CXCR7 expression among distinct histopathological types (well-differentiated vs. moderately-to-poorly differentiated adenocarcinoma, P﹥0.01). Therefore, the evidence obtained from the present study supports involvement of the upregulated CXCR7 expression in colon tumorigenesis and lymph node metastasis.
Collapse
Affiliation(s)
- Hong Xian Wang
- Department of Surgery, Nanshan Affiliated Hospital, Guangdong Medical College, Shenzhen, Guangdong 518052, P.R. China
| | - Lin Yu Tao
- Department of Surgery, Nanshan Affiliated Hospital, Guangdong Medical College, Shenzhen, Guangdong 518052, P.R. China
| | - K E Qi
- Department of Surgery, Nanshan Affiliated Hospital, Guangdong Medical College, Shenzhen, Guangdong 518052, P.R. China
| | - Hao Yun Zhang
- Department of Surgery, Nanshan Affiliated Hospital, Guangdong Medical College, Shenzhen, Guangdong 518052, P.R. China
| | - Duo Feng
- Department of Surgery, Nanshan Affiliated Hospital, Guangdong Medical College, Shenzhen, Guangdong 518052, P.R. China
| | - Wen Jun Wei
- Department of Surgery, Nanshan Affiliated Hospital, Guangdong Medical College, Shenzhen, Guangdong 518052, P.R. China
| | - Heng Kong
- Department of Surgery, Nanshan Affiliated Hospital, Guangdong Medical College, Shenzhen, Guangdong 518052, P.R. China
| | - Tian Wen Chen
- Department of Surgery, Nanshan Affiliated Hospital, Guangdong Medical College, Shenzhen, Guangdong 518052, P.R. China
| | - Qiu Sheng Lin
- Department of Surgery, Nanshan Affiliated Hospital, Guangdong Medical College, Shenzhen, Guangdong 518052, P.R. China
| | - Dao Jin Chen
- Department of Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410083, P.R. China
| |
Collapse
|